Granulocyte transfusions (GTX) have been previously reported to be a therapeutic modality for patients with severe infections in prolonged aplasia. [1] [2] [3] A persistent, poorly controlled bacterial or fungal infection prior to allogeneic HSCT (allo-HSCT) is a severe risk factor for morbidity and mortality. It was our hypothesis that pre-emptive GTX can enable patients to undergo a lifesaving allo-HSCT. Therefore, we developed a protocol for patients with persistent, poorly controlled infections to undergo a HCT under the coverage of GTX. Here we report our experience with three children who underwent such a procedure.
Patients with poorly controlled fungal or bacterial infections prior to all-HSCT (for any indication and for whom a delay of the HCT was unacceptable) were selected for pre-emptive GTX in addition to antimicrobial treatment. Donors were family volunteers and were selected on the following criteria: age 16-70 years, viral status (including CMV and HIV), ABO compatibility and the physical condition (examined by a trained physician). When selected, they were all asked to sign an informed consent. Preferably, ABO-compatible and CMVnegative donors were used when the patient was also CMV negative. In case of ABO incompatibility, preferably an anti-A/B titre of p1:64 was accepted (for donors and recipient).
Regarding the stimulation and apheresis procedure, donors were treated with 480 mg G-CSF and 7.5 mg dexamethasone on the evening prior to the apheresis. The apheresis procedure was similar to the procedure described by Price et al. 4 The target amount of cells harvested was 5 Â 10 10 m
À2
. After harvesting, the granulocyte product was irradiated (25 Gy). Granulocytes were infused in 1 2 -1 h In case of ABO incompatibility, granulocytes were infused in 3 h.
For GTX and followup, GTX was given three times weekly. In case the persistent infection flared, frequency was increased to daily infusions. After infusion, at 1 h, 1 and, 2 days, the ANC was measured. Recipients received G-CSF (10 mg/kg/day) starting at day þ 7 after stem cell graft infusion. GTX were stopped when ANC was above 500/ml. Patients were closely monitored for flares of the underlying persistent infection and for all transplantationrelated morbidities such as GvHD.
Between December 2003 and November 2004, 35 HCTs were performed in our centre. Three patients fulfilled the selection criteria for GTX (Table 1a) . In all three patients, chronic infection was present at the time of HCT. Patient 1 was a 10-year-old boy with X-CGD who had active Staphylococcus aureus liver abscesses that were treated with linezolid for more than 1 year. This helped to control the abscesses, but did not cure them: abcesses remained visible on ultrasound and both CRP and ESR remained elevated, with fever present now and then. Four years previously, he underwent a HCT with the same sibling donor after reduced intensity conditioning, but showed autologous recovery. Patient 2 was a 5-yearold boy with Blackfan-Diamond, who was persistently neutropenic after first HCT (with sibling donor) with autologous recovery. He had chronic pulmonary Aspergillosis (galactomanan positive in serum: ratio 41 as well as positive cultures from BAL) despite treatment with G-CSF, ambisome and voriconazol. Due to the persistent neutropenia and active infection, this patient started on day À21 with GTX. Patient 3 was a 13-year-old boy with relapsed ALL who had chronic (poorly controlled: culture positive) Mucormycosis infection of his left arm despite partial superficial surgical resection and treatment with amphotericin-B.
For these patients three, five and five donors were used, to receive five, nine or 10 GTX, respectively (Table 2) . Donors (Table 1b) underwent an apheresis with a median of two times (range 1-4). For patient 1, there were neither ABO-compatible nor CMV-negative donors available. Patient 2 received a total of seven GTX pre-transplant and three post-transplant. He came out of aplasia rather quickly, at day þ 7.
In none of the patients a transfusion-related reaction was seen ( Table 2 ). All HSCTs were successful with 100% donor chimerism. None of the chronic poorlycontrolled infections flared up. In patient 3, the granulocyte counts 1 h after GTX were lower in comparison to the other two patients, although the amount of granulocytes given was comparable. No HLA antibodies were found. He developed a GvHD grade 3 (skin and liver), successfully treated with steroids, and has persistent (but improving) thrombocytopenia. The granulocyte donors did not have any complications from the apheresis procedure.
We have reported three cases in which successful preemptive GTX were given in patients with persistent, poorly controlled infections and therefore at risk for post-HCT complications/mortality. In these patients no flare of the infection was seen. Although one of the patients developed GvHD, no other complications were seen. Even in patient 1, for whom only ABO-incompatible donors with high iso-haemaglutinine levels were available, no haemolysis or transfusion-related reactions were seen. For the donors the procedure was well tolerated.
There have been reports of successful HCTs in patients with severe infections who were treated with GTX. 5, 6 Most reports in literature aim for 2-4 Â 10 10 harvest cells. 7, 8 We aimed for a higher amount (5 Â 10 10 /m 2 ) as described by Price, 4 and collected a median of 3.8 Â 10 10 /m 2 (range 0.6-11.3) cells in our three patients. Our peripheral blood increment was lower than the increment described in Price's article. This is most probably due to the fact that Price transfused daily as opposed to our three times a week transfusion regimen. Our donors were all family members and we opted for a three times a week regimen to relieve the burden of the donors somewhat. Our protocol however indicated a switch to daily GTX if there were any signs of a flare-up of the chronic infection. With this dose, granulocytes were almost continuously present, except in patient 3. Perhaps the active chronic mucormycosis was the cause of consumption of these granulocytes. As reported in the literature, 4,9,10 GTX was a safe procedure in our setting. 
Gran ¼ granulocytes; L+1 h ¼ leukocytes 1 h post-GTX; L+1d ¼ day 1 post-GTX.
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